Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | FPR3 | P25089 | 2/20 | 0.40 |
| ▸ | FPR2 | P25090 | 2/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21397628 | 1.00 | ESR2 (0.43) | ESR2USP30GPR119ALKHDAC1 | |
| SCHEMBL22789685 | 0.91 | USP30 (0.41) | ESR2USP30GPR119ALKHDAC1 | |
| SCHEMBL22792391 | 0.90 | ESR2 (0.52) | ESR2USP30GPR119HDAC1HDAC8 | |
| SCHEMBL30111061 | 0.90 | ESR2 (0.52) | ESR2USP30GPR119HDAC1HDAC8 | |
| SCHEMBL1466048 | 0.88 | ESR2 (0.42) | ESR2USP30HDAC1FPR3FPR2 | |
| SCHEMBL22792848 | 0.87 | GPR119 (0.43) | ESR2USP30GPR119HDAC1HDAC8 | |
| SCHEMBL22493761 | 0.86 | ALDH1A1 (0.48) | ESR2USP30GPR119NR1H2BACE1 | |
| SCHEMBL21856129 | 0.86 | MEN1 (0.46) | ESR2USP30GPR119HDAC1HDAC8 | |
| SCHEMBL22770482 | 0.86 | NR1H2 (0.53) | ESR2USP30GPR119HDAC1HDAC8 | |
| SCHEMBL22440522 | 0.86 | GPR119 (0.43) | ESR2USP30GPR119HDAC1NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098049-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20250223285-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | JACOBIO PHARMACEUTICALS CO LTD (CN) | 2025-07-10 | — | — | US | disclosed |
| CN-120202197-A | Nitrogen-containing spiro compound, pharmaceutical composition and application thereof | 北京普祺医药科技股份有限公司 | 2025-06-24 | — | — | CN | disclosed |
| EP-3601239-B1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | JACOBIO PHARMACEUTICALS CO LTD (CN) | 2024-07-31 | — | — | EP | disclosed |
| WO-2024099404-A1 | NITROGEN-CONTAINING SPIROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 北京普祺医药科技股份有限公司 | 2024-05-16 | — | — | WO | disclosed |
| CN-117384165-A | Chimeric compound for EGFR protein targeted degradation, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2024-01-12 | — | — | CN | disclosed |
| EP-4288436-A1 | TRICYCLIC COMPOUNDS AND USES THEREOF | HUTCHMED Limited (CN) | 2023-12-13 | — | — | EP | disclosed |
| CN-117209470-A | SHP2 phosphatase allosteric inhibitor | 北京盛诺基医药科技股份有限公司 | 2023-12-12 | — | — | CN | disclosed |
| CN-117209471-A | SHP2 phosphatase allosteric inhibitor | 北京盛诺基医药科技股份有限公司 | 2023-12-12 | — | — | CN | disclosed |
| CN-117209475-A | SHP2 phosphatase allosteric inhibitor | 北京盛诺基医药科技股份有限公司 | 2023-12-12 | — | — | CN | disclosed |
| CN-116940573-A | Tricyclic compounds and uses thereof | 和记黄埔医药（上海）有限公司 | 2023-10-24 | — | — | CN | disclosed |
| CN-115969853-A | Novel heterocyclic derivatives useful as SHP2 inhibitors | 北京加科思新药研发有限公司 | 2023-04-18 | — | — | CN | disclosed |
| CN-115721648-A | Novel heterocyclic derivatives useful as SHP2 inhibitors | 北京加科思新药研发有限公司 | 2023-03-03 | — | — | CN | disclosed |
| CN-112174935-B | Heterocyclic derivatives useful as SHP2 inhibitors | 北京加科思新药研发有限公司 | 2022-12-06 | — | — | CN | disclosed |
| CN-112409334-B | Heterocyclic derivatives useful as SHP2 inhibitors | 北京加科思新药研发有限公司 | 2022-12-02 | — | — | CN | disclosed |
| WO-2022089406-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海青煜医药科技有限公司 | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250223285-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | PTPN5, PTPN1, PTPRJ | ESR2 3034/4885USP30 1145/4885GPR119 1764/4885 |
| US-20260098049-A1 | KRAS MODULATING COMPOUNDS | KRAS, NRAS, HRAS | ESR2 2696/4885USP30 2549/4885GPR119 2528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.